Big Pharma Giants All Top Analysts’ Expectations as Pharmaceutical Industry Continues to Price-Gouge and Fight Market-Based Solutions to Lower Drug Prices In another round of blockbuster earnings for the second quarter of the year, Big Pharma giants Pfizer, Merck, Bristol Myers Squibb, GlaxoSmithKline and Sanofi all reported stellar earnings that topped Wall Street analysts’ expectations. […]
Big Pharma Kicks Off Q2 Earnings Calls After More than 100 Price Hikes to Start July This week, Roche, Novartis, and Johnson & Johnson kicked off the first round of Big Pharma earnings reports for the second quarter of 2022. After drug companies raised prices on more than 100 brand-name pharmaceuticals in the first week […]
Joint Effort Aims to Curb Anti-Competitive Tactics Used by Brand Name Drug Companies to Block More Affordable Alternatives In case you missed it, the U.S. Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA) recently announced a joint effort to crack down on Big Pharma’s anti-competitive gamesmanship of the patent system. The […]
PhRMA Ads Falsely Claim the Industry’s Egregious Pricing Practices Don’t Drive Prescription Drug Inflation Amid unprecedented momentum to hold Big Pharma accountable and lower prescription drug prices, the pharmaceutical industry is once again trying to deflect blame with false rhetoric meant to evade responsibility for brand name drug companies’ egregious practices. New advertising from the […]
Committee Report Shows How Brand Name Drug Company Further Juiced Profits on Blockbuster Drug Already Known as a Case Study for Big Pharma’s Greed In case you missed it, on Thursday the U.S. Senate Committee on Finance released an interim report examining strategies employed by Big Pharma company AbbVie to avoid paying taxes on profits […]
Lawmakers Can Highlight Tactics Designed to Block More Affordable Alternatives from the Market — Add to Momentum for Market-Based Solutions In Washington this week, Congress will hold a pair of hearings on the patent system, offering an opportunity for lawmakers to detail Big Pharma’s anti-competitive practices that drive higher prescription drug prices and add to […]
Big Pharma Trots Out Tired, Dishonest Arguments Designed to Evade Accountability, Keep Prices High As lawmakers in Congress continue to weigh market-based solutions to lower prescription drug prices, Big Pharma is once again doubling down on bogus blame game tactics — designed to evade accountability for brand name drug companies’ egregious practices and keep prices […]
Federal Trade Commission Workshop Highlights How Brand Name Drug Companies Game the System to Keep Prices High — Demonstrating the Urgency for Congress to Act This week, the Federal Trade Commission and U.S. Department of Justice Antitrust Division hosted a two-day virtual workshop on enforcing antitrust laws in the pharmaceutical industry. The workshop brought together […]
FTC Workshop Can Highlight How Brand Name Drug Companies Employ Anti-Competitive Tactics to Game the System — Driven by Focus on Profits Over People This week, the Federal Trade Commission (FTC) is scheduled to host a two-day workshop titled, “The Future of Pharmaceuticals: Examining the Analysis of Pharmaceutical Mergers,” where experts from the FTC and […]
Nearly Half of All New Brand Name Drugs Cost More Than $150,000 Per Year In case you missed it, a new academic study published in The Journal of the American Medical Association (JAMA) from researchers affiliated with Harvard University and Brigham and Women’s Hospital showcases how Big Pharma increasingly engages in egregious pricing practices on […]